Our mission is to awaken hope for people living with Alzheimer's Disease.

Executive Leadership

Ed Large, PhD - Founder & Chief Science Officer

Ed Large is co-founder of Oscillo, where his work focuses on combining the power of music with the latest breakthroughs in neuroscience to fight Alzheimer’s disease. He also directs the Music Dynamics Laboratory and the Theoretical Neuroscience Laboratory at the University of Connecticut, where he is professor in the departments of Psychological Sciences and Physics. Ed studied mathematics at Colorado College and classical guitar performance at Southern Methodist University. During his PhD studies at The Ohio State University, Ed pioneered an approach to understanding how music affects the brain, combining neural networks, nonlinear dynamics, and experimental psychology. He completed his postdoctoral studies in auditory neuroscience at University of Pennsylvania. Previously, Ed was a professor at the NIH-funded Center for Complex Systems and Brain Sciences at Florida Atlantic University.

Dr. Large is a global thought leader in the psychology and neuroscience of music. He has spent the past 30 years studying how music entrains—or synchronizes—brain rhythms. His research is published in Journal of Neuroscience, Psychological Review, Physica D, Music Perception, and many others, and he has been granted several US and International patents. He regularly travels around the world to lecture on his research, and he has received recognition for his work, including a National Research Service Award, a National Science Foundation CAREER Award, and a Fulbright Chair in the Science and Technology of Music. He has served on the scientific advisory board of the Institute for Music and Neurologic Function, and as President of the Society for Music Perception and Cognition.

Michael Canzian - Chief Executive Officer

Michael’s primary expertise is corporate buyout and private equity capital development, specializing in the provisioning of onsite operational management capability to achieve optimal levels of growth and return. Most recently, Michael served as interim CEO of Dendreon Pharmaceuticals, LLC, a pioneer in immunotherapy focused on extending the lives of metastatic prostate cancer patients. As interim CEO, Michael resolved unique business challenges to position the business for growth and global expansion to reach $1B+. He reassessed clinical trial criteria to pursue a dual compendia/label strategy, developed a phase 1 commercial launch strategy, introduced cost control measures, and evaluated regulatory and patient access solutions. Michael’s current focus is on capital raising and operational consultative opportunities in the Biosciences and Biotech markets.

Ji Chul Kim, PhD - Chief Technology Officer

Ji Chul Kim, co-founder of Oscillo, is one of the world’s leading experts on oscillatory neural networks. Ji Chul studied physics and music theory at Seoul National University, and received his PhD in Music Theory and Cognition from Northwestern University. He completed his postdoctoral studies at the University of Connecticut in psychology and neuroscience. His research includes computational neuroscience, dynamical systems, and auditory modeling, focusing on music perception and cognition. He leads the development of Oscillo’s core technology, software libraries, APIs, and embedded systems.

Sumeet Vadera, MD - Chief Medical Officer

Sumeet Vadera, M.D. is a forward-thinking and multifaceted Associate Professor of Neurological Surgery who is active in education and clinical research. He is a published and award-winning speaker, presenter, and blogger who has written over 60 peer-reviewed scientific articles over the last 15 years. Sumeet has a passion for improving the care of patients with devastating and difficult to treat neurological diseases. Dr. Vadera completed his neurosurgery training and epilepsy surgery fellowship at the Cleveland Clinic and most recently received an MBA from UCLA-Anderson.

Brian Groch- Chief Operating Officer

Brian brings 30+ years of senior experiencein healthcare and life science industries, including product commercialization,developing, and executing global sales strategies, business development, andoperations. Most recently, Brian served as President of Shield TherapeuticsInc. and Chief Commercial Officer of Shield Therapeutics Plc where he wasinstrumental in the raise of $45 million to successfully establish the USentity of Shield Therapeutics and launch their first pharmaceutical product,Accrufer. Prior to Shield, Brian served as Executive Vice President BusinessDevelopment and Chief Commercial Officer at Acasti Pharma Inc., abiopharmaceutical company developing innovative drugs for cardiometabolicdiseases. Prior to Acasti, Brian served as Executive Vice President and ChiefCommercial Officer of Veru Inc., a urology, oncology, and female healthproducts company, where he was responsible for leading the development andexecution of the company’s commercial strategy. Under his leadership, Veruexperienced rapid growth in sales of the Company’s women’s health product.Brian also served as Chief Commercial Officer for Telesta Therapeutics, wherehe led the development and implementation of the global commercial strategy,Previously, Brian served as Vice President of Commercial Operations and MarketAccess for Horizon, where he oversaw operations for the buildout of the orphanbusiness group. This included the integration of two acquisitions valued atover $1.9 billion. Brian also has held the position of Head of Market Accesswith Dendron and management roles with pharmaceutical giants Novartis and Merck& Co. He holds a M.S. in Healthcare Administration and Marketing fromCentral Michigan University as well as a B.S. in Physiology from CentralMichigan University.  

Mark Costanzo - Chief Financial Officer

Mark is a multifaceted global finance professional with more than 20 years of experience in private and public enterprises, venture capital, and private equity. His background includes operations, systems and process design, merger and acquisition negotiation, and all facets of capital and venture funding. He has served a broad range of industries including healthcare, manufacturing, finance, government contracting, fintech, and emerging technology—all of which have contributed to his keen sense of general management and problem-solving. As Oscillo CFO, Mark oversees cash management and forecasting, budgeting and expense control, and tax planning. He leads all efforts related to securing financing and raising operating capital. He manages the company’s compensation plan and KPIs, and is the primary board and investor communications liaison.

Board of Directors

Kim Cooke

Kim Cooke is an investor, philanthropist, and Founder / Managing Director of Blue Water Capital and Cooke, LLC. Kim was trained as a trial lawyer, but switched course 25 years ago to a transactional focus and ultimately entered the private equity business. Over the past two decades he has invested over $100 million in over 30 companies, guiding, and mentoring people who are passionate about their ideas and ideals. Cooke, LLC concentrates on impact investing, seeking to “do well by doing good”.

Kim also serves on several not for profit boards, including Living Hope International and the Northville Educational Foundation. Kim received his Juris Doctor from Michigan State University College of Law and LLM from the American University, Washington College of Law with highest honors. He is admitted to practice law in the State of Michigan, the Commonwealth of Virginia, and the District of Columbia.

Bill Wade

Bill is the founder and CEO of Company.com. Founded in 2008, Company.com specializes in aggregating and integrating best-in-class software and services for small businesses through its proprietary Digital Experience Platform (DXP). Through both direct acquisition and distribution channel partner relationships, this platform allows hundreds of thousands of small businesses to discover, access and manage multiple products from one integrated dashboard and billing platform. The DXP platform serves over 450,000 businesses in the United States and Company.com powers the delivery of services to customers of companies like Legalzoom, Yext, First Data, FIS Global, OfficeDepot, OfficeMax, and Paysafe.

Bill founded over 25 companies over several decades focused on innovation and technology advancement in the fintech, payments, B2B services, real estate, construction, Biotech, hospitality, data security and compliance, social media, analytics, gaming, and e-commerce sectors.

Scientific Advisors

Psyche Loui, PhD

Psyche is a cognitive scientist, neuroscientist, and musician. She received her BS in psychology and music from Duke University and her PhD in psychology from University of California at Berkeley. She completed her postdoctoral studies in neurology at Beth Israel Deaconess Medical Center and Harvard Medical School. Psyche is currently the Director of the Music, Imaging, and Neural Dynamics Laboratory (MIND Lab) at Northeastern University, and a core member of Northeastern University’s Biomedical Imaging Center and Center for Cognitive and Brain Health. Her research addresses music perception, expectation, learning, and reward in the normal brain as well as in special populations with neurological and/or psychiatric disorders. Psyche is a member of the AARP’s Global Council on Brain Health, and a core member of the Sound Health Initiative at the National Institutes of Health. Psyche directs Oscillo’s NSF-funded pre-clinical efficacy trial in the MIND lab at Northeastern University.

Maiya Geddes, MD

Dr. Geddes is a clinician scientist and an assistant professor in the Department of Neurology and Neurosurgery at McGill University. Dr. Geddes obtained an MD at the University of British Columbia before completing a residency in adult neurology at McGill University. She completed a CIHR-funded postdoctoral research fellowship at the McGovern Institute for Brain Research at the Massachusetts Institute of Technology. Dr. Geddes obtained subspecialty clinical fellowship training in behavioural neurology and neuropsychiatry at the Center for Brain/Mind Medicine at the Brigham and Women’s Hospital and Harvard Medical School, where she then joined the faculty in 2017. The goal of Dr. Geddes’ research program is to determine the brain mechanisms underlying the interaction between motivation and cognition in aging. Dr. Geddes has received recognition for her research including a Career Development Award from the American Neuropsychiatric Association and a Future Leader Award from the Canadian Conference on Dementia. Her research program is funded by the National Institutes of Health. Maiya consults on Oscillo’s NSF-funded pre-clinical efficacy trial at Northeastern University.